Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains.
ELISA
free light chains
immunoassays
method comparison
nephelometry
reference intervals
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
received:
18
08
2023
accepted:
03
11
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
aheadofprint
Résumé
Free light chain (FLC) assays and the ratio of κ/λ are recommended for diagnosis, prognosis and monitoring of plasma cell dyscrasias (PCD). Limited data exists on FLC clinical specificity in patients diagnosed with other conditions. We assessed the κ, λ, and κ/λ FLC ratio using the FreeLite assay and the Sebia FLC ELISA assay in 176 patients with clinical presentations of fatigue, anemia, polyclonal hypergammaglobulinemia, joint disorders, kidney disease and non PCD-cancers with no monoclonal protein observed on serum protein electrophoresis or MASS-FIX immunoglobulin isotyping. Manufacturer defined reference intervals (RI) and glomerular filtration rate (GFR) specific RI (renal RI) were utilized. For the κ/λ ratio, 68.7 % (121/176) of specimens on the FreeLite and 87.5 % (154/176) of specimens on the Sebia assay were within RI. For κ, 68.2 % (120/176) and 72.2 % (127/176) of results were outside RI for FreeLite and Sebia respectively. For λ, 37.5 % (66/176) and 84.1 % (148/176) of FreeLite and Sebia results were outside RI. With FreeLite and Sebia, patients with kidney disease (n=25) had the highest κ/λ ratios. 44 patients (25.0 %) had GFR <60 mL/min/BSA. When renal RI were applied, 13.6 % had a FLCr outside the renal RI with FreeLite, and 4.5 % with Sebia. In a cohort of patients with signs and symptoms suggestive of PCDs, but ultimately diagnosed with other conditions, Sebia FLC had improved clinical specificity relative to FreeLite, if one was using an abnormal κ/λ ratio as a surrogate for monoclonality.
Identifiants
pubmed: 38044587
pii: cclm-2023-0912
doi: 10.1515/cclm-2023-0912
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48. https://doi.org/10.1016/s1470-2045(14)70442-5 .
doi: 10.1016/s1470-2045(14)70442-5
Katzmann, JA, Clark, RJ, Abraham, RS, Bryant, S, Lymp, JF, Bradwell, AR, et al.. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437–44. https://doi.org/10.1093/clinchem/48.9.1437 .
doi: 10.1093/clinchem/48.9.1437
Rajkumar, SV, Kyle, RA, Therneau, TM, Melton, LJ, Bradwell, AR, Clark, RJ, et al.. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–7. https://doi.org/10.1182/blood-2005-03-1038 .
doi: 10.1182/blood-2005-03-1038
Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–46. https://doi.org/10.1016/s1470-2045(16)30206-6 .
doi: 10.1016/s1470-2045(16)30206-6
Muchtar, E, Dispenzieri, A, Gertz, MA, Kumar, SK, Buadi, FK, Leung, N, et al.. Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc 2021;96:1546–77. https://doi.org/10.1016/j.mayocp.2021.03.012 .
doi: 10.1016/j.mayocp.2021.03.012
Larsen, JT, Kumar, SK, Dispenzieri, A, Kyle, RA, Katzmann, JA, Rajkumar, SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941–6. https://doi.org/10.1038/leu.2012.296 .
doi: 10.1038/leu.2012.296
Willrich, MAV, Murray, DL, Rajkumar, SV, Bryant, SC, Larson, D, Pazdernik, V, et al.. Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma. Blood Cancer J 2022;12:127. https://doi.org/10.1038/s41408-022-00722-5 .
doi: 10.1038/s41408-022-00722-5
Cotten, SW, Shajani-Yi, Z, Cervinski, MA, Voorhees, T, Tuchman, SA, Korpi-Steiner, N. Reference intervals and diagnostic ranges for serum free kappa and free lambda immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study. Clin Biochem 2018;58:100–7. https://doi.org/10.1016/j.clinbiochem.2018.06.003 .
doi: 10.1016/j.clinbiochem.2018.06.003
Fleming, CKA, Swarttouw, T, de Kat Angelino, CM, Jacobs, JFM, Russcher, H. Method comparison of four clinically available assays for serum free light chain analysis. Clin Chem Lab Med 2019;58:85–94. https://doi.org/10.1515/cclm-2019-0533 .
doi: 10.1515/cclm-2019-0533
Sandfeld-Paulsen, B, Aggerholm-Pedersen, N, Samson, MH, Moller, HJ. A cohort study of free light chain ratio in combination with serum protein electrophoresis as a first-line test in general practice. Cancers 2022;14. https://doi.org/10.3390/cancers14122930 .
doi: 10.3390/cancers14122930
Hutchison, CA, Harding, S, Hewins, P, Mead, GP, Townsend, J, Bradwell, AR, et al.. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684–90. https://doi.org/10.2215/cjn.02290508 .
doi: 10.2215/cjn.02290508
Hutchison, CA, Plant, T, Drayson, M, Cockwell, P, Kountouri, M, Basnayake, K, et al.. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;9:11. https://doi.org/10.1186/1471-2369-9-11 .
doi: 10.1186/1471-2369-9-11
Long, TE, Indridason, OS, Palsson, R, Rognvaldsson, S, Love, TJ, Thorsteinsdottir, S, et al.. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J 2022;12:133. https://doi.org/10.1038/s41408-022-00732-3 .
doi: 10.1038/s41408-022-00732-3
Lutteri, L, Jacobs, JFM. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease. Clin Chem Lab Med 2018;56:e232–4. https://doi.org/10.1515/cclm-2018-0040 .
doi: 10.1515/cclm-2018-0040
Jacobs, JF, Hoedemakers, RM, Teunissen, E, Te Velthuis, H. N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med 2014;52:853–9. https://doi.org/10.1515/cclm-2013-0864 .
doi: 10.1515/cclm-2013-0864
Kyle, RA, Therneau, TM, Rajkumar, SV, Larson, DR, Plevak, MF, Offord, JR, et al.. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9. https://doi.org/10.1056/nejmoa054494 .
doi: 10.1056/nejmoa054494
Inker, LA, Eneanya, ND, Coresh, J, Tighiouart, H, Wang, D, Sang, Y, et al.. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385:1737–49. https://doi.org/10.1056/nejmoa2102953 .
doi: 10.1056/nejmoa2102953
Kohlhagen, M, Dasari, S, Willrich, M, Hetrick, M, Netzel, B, Dispenzieri, A, et al.. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med 2020;59:155–63. https://doi.org/10.1515/cclm-2020-0581 .
doi: 10.1515/cclm-2020-0581
Mills, JR, Kohlhagen, MC, Dasari, S, Vanderboom, PM, Kyle, RA, Katzmann, JA, et al.. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 2016;62:1334–44. https://doi.org/10.1373/clinchem.2015.253740 .
doi: 10.1373/clinchem.2015.253740
Murray, D, Dispenzieri, A, Kumar, S, Gill, H, Vachon, C, Snyder, M, et al.. Free light chain assay drift: potential for misdiagnosis? J Appl Lab Med 2020;5:1411–3. https://doi.org/10.1093/jalm/jfaa093 .
doi: 10.1093/jalm/jfaa093
Rindlisbacher, B, Schild, C, Egger, F, Bacher, VU, Pabst, T, Leichtle, A, et al.. Serum free light chain assay: shift toward a higher κ/λ ratio. J Appl Lab Med 2019;5:114–25. https://doi.org/10.1093/jalm.2019.029330 .
doi: 10.1093/jalm.2019.029330
Rozenova, K, Willrich, M, Snyder, M, Dasari, S, Kourelis, T, Rajkumar, SV, et al.. Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance. J Appl Lab Med 2023;8:742–50. https://doi.org/10.1093/jalm/jfad027 .
doi: 10.1093/jalm/jfad027
Solling, K. Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest 1976;36:447–52. https://doi.org/10.3109/00365517609054462 .
doi: 10.3109/00365517609054462
Caponi, L, Koni, E, Romiti, N, Paolicchi, A, Franzini, M. Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent. Clin Chem Lab Med 2018;57:221–9. https://doi.org/10.1515/cclm-2018-0412 .
doi: 10.1515/cclm-2018-0412
Gatt, ME, Kaplan, B, Yogev, D, Slyusarevsky, E, Pogrebijski, G, Golderman, S, et al.. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. Br J Haematol 2018;182:86–92. https://doi.org/10.1111/bjh.15387 .
doi: 10.1111/bjh.15387
Kaplan, B, Jacobs, JFM. FLC polymerization: another hurdle towards standardization of FLC measurements. Clin Chim Acta 2021;515:42–3. https://doi.org/10.1016/j.cca.2020.12.030 .
doi: 10.1016/j.cca.2020.12.030
Rollborn, N, Jakobsson, J, Campbell, A, Nordin, G, Karlsson, M, Larsson, A, et al.. Accuracy of determination of free light chains (kappa and lambda) in plasma and serum by Swedish laboratories as monitored by external quality assessment. Clin Biochem 2023;111:47–53. https://doi.org/10.1016/j.clinbiochem.2022.10.003 .
doi: 10.1016/j.clinbiochem.2022.10.003
Kyle, RA, Larson, DR, Therneau, TM, Dispenzieri, A, Melton, LJ3rd, Benson, JT, et al.. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 2014;1:e28–36. https://doi.org/10.1016/s2352-3026(14)70001-8 .
doi: 10.1016/s2352-3026(14)70001-8
National Institutes of Health NIoDaDaKDU . 2022 USRDS annual data report: epidemiology of kidney disease in the United States ; 2022.
Molina-Andujar, A, Robles, P, Cibeira, MT, Montagud-Marrahi, E, Guillen, E, Xipell, M, et al.. The renal range of the kappa/lambda sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease. BMC Nephrol 2020;21:111. https://doi.org/10.1186/s12882-020-01771-3 .
doi: 10.1186/s12882-020-01771-3